
Better Late Than Never – Richard Ransohoff
What does it take to turn a scientific discovery into a treatment that changes patients’ lives? In this episode of SpreadLove in Organizations, Naji Gehchan sits down with Richard Ransohoff, neurologist, neuroscientist, and biotech innovator, to explore a career at the intersection of medicine, immunology, neuroscience, and biotechnology. Richard shares his unconventional journey from studying literature and poetry to becoming a physician-scientist and a leading contributor to research on multiple sclerosis (MS), neuroinflammation, and the immune system. His story highlights how curiosity, unexpected opportunities, and a willingness to follow new questions can shape a meaningful career.
Richard reflects on the scientific breakthroughs, collaborations, and leadership experiences that helped advance understanding and treatment of multiple sclerosis, including the role of chemokines, animal models of disease, and therapies. Drawing on his experiences in academic research, at the Cleveland Clinic, in biotechnology, and with Third Rock Ventures, he explains how promising scientific discoveries can be translated into new medicines and innovative biotech companies. The conversation explores the importance of identifying genuine unmet medical needs, combining scientific rigor with strategic thinking, building complementary teams, and recognizing the serendipity that often drives medical progress. For scientists, physicians, biotech entrepreneurs, and healthcare leaders, Richard offers valuable perspectives on translational research, innovation, and the challenges of bringing new treatments to patients.
At its heart, this episode is about leadership, empathy, resilience, and making a difference for patients. Richard shares his perspective on what makes an effective leader, why authenticity matters, and how to keep moving forward when scientific and professional journeys become difficult. His reflections connect scientific excellence with a deeper sense of purpose: advancing knowledge is meaningful when it ultimately improves human lives.
"Day does follow night."
MEET OUR GUEST Richard Ransohoff, Venture Partner, Third Rock Ventures.
Richard M. Ransohoff is presently (2018-present) Venture Partner at Third Rock Ventures. At Third Rock, Ransohoff works on company creation with particular focus on serious unmet medical need in neurology, immunology and neuropsychiatry. He is a scientific Co-Founder for Abata Therapeutics, where he served for two years as interim Chief Medical Officer (CMO) and member of the Executive Leadership Team. At Abata, he continues as Clinical Advisor. He helped launch Trace Neuroscience, where he serves on the Scientific Advisory Board (SAB).
From 1984-2014 Ransohoff was Staff Member at Cleveland Clinic where he founded and directed the Neuroinflammation Research Center (2005-2014) in the Lerner Research Institute and served (1984-2014) as Staff Neurologist, Cleveland Clinic Mellen Center for MS Treatment and Research. He lists >460 scientific articles and reviews in PubMed (July 2026 H-index 154; >125,000 citations) and trained >70 students and post-docs who hold positions in science, medicine and industry. Ransohoff serves on the American Brain Foundation (ABF) Board of Trustees and Research Advisory Committee, as well as the Board of Directors for the American Society for Neurotherapeutics (ASENT). He was previously on SABs for the Keystone Symposia, Chemocentryx, Vertex, LeukoSite, German Center for Research in Neurodegenerative Disease (DZNE) and the Gladstone Institute for Neurological Diseases (GIND) at UCSF. Ransohoff served on both NIH and National MS Society study section for many years and continues service on Special Emphasis Panels. He was Associate Editor of Neurology for inflammatory and infectious conditions for 10 years, before becoming founding Editor for Neurology: Neuroimmunology and Neuroinflammation. He continues on editorial boards for Trends in Immunology, Trends in Molecular Medicine (until 2024) and Journal of Neuroimmunology. Dr. Ransohoff is also Adjunct Professor, Molecular Medicine; Genetics and Genome Sciences; and Pathology at the Case Western Reserve University (CWRU) School of Medicine and Cleveland Clinic Lerner College of Medicine.
Dr. Ransohoff joined Biogen as Senior Research Fellow in 2014 and moved to Third Rock at the end of 2017. At the time he transitioned, he served as VP, and Research/Early Development (RED) Unit Head for Neuroimmunology & MS/Pain/Acute Neurology. He led a group of >45 scientists and clinicians in identifying and prosecuting neuroinflammatory targets for treatment of neurological disease and pain, bringing those relevant for acute neurology indications through phase II proof of concept (PoC). During this time, he directed the transformation of the neuroinflammation portfolio, successfully bringing 5 compounds (internally developed and externally identified) into the clinic as well as directing activities in blood-brain barrier (BBB) function, progressive multifocal leukoencephalopathy (PML) risk mitigation and novel screening technologies for glial targets, in addition to basic neuroinflammation biology.
Among other awards, Ransohoff was named in “Best Doctors” from 1996-2014 for his expertise in patient care for MS. He received the John and Samuel Bard Award in Science or Medicine, Bard College (2002), F.E. Bennet American Neurological Association Lectureship (2009), the John J. Dystel Award for MS Research from the National MS Society and American Academy of Neurology (2012) and the Distinguished Alumni Award, CWRU School of Medicine (2018). He’s a Fellow of the American Association for the Advancement of Science (AAAS) and member of the Association of American Physicians.
Richard is married to Margaret Seidler Ransohoff (1988), has two daughters, Amy (born 1989) and Lena (1994). The family recently greeted Amy’s daughters Madeleine (2022) and Abigail (2025).
More episodes from "SpreadLove In Organizations - Healthcare Leadership"



Don't miss an episode of “SpreadLove In Organizations - Healthcare Leadership” and subscribe to it in the GetPodcast app.








